Introduction {#s1}
============

The COVID-19 outbreak emerged in 2019. The causative pathogen for COVID-19 was identified as a novel beta coronavirus, SARS-CoV-2, which is genetically related to severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and Middle East respiratory syndrome coronavirus (MERS-CoV; Lu et al., [@B26]). Furthermore, SARS-CoV-2 and SARS-CoV-1 share the same cellular receptor, angiotensin-converting enzyme 2 (ACE2), despite amino acid variation at some key residues (Chan et al., [@B7]). All three coronaviruses can cause severe infectious respiratory disease. Currently, COVID-19 has spread across multiple countries (Holshue et al., [@B20]; Hui et al., [@B21]), and it is reasonable to speculate that some pregnant women have been infected. However, little is known about the clinical course and the obstetric management of COVID-19 in pregnancy. Available data could be drawn from cases of pregnancy complicated with SARS and MERS. This review was conducted to investigate the clinical course and outcome of COVID-19 in pregnancy and to discuss several drugs that could be used for pregnant women with COVID-19.

Comparison of COVID-19, SARS, and MERS In pregnancy {#s2}
===================================================

We searched PubMed and the China National Knowledge Infrastructure Database for literature that was published up to March 30, 2020, using the keywords "coronavirus," "pregnant," or "neonate." Data about pregnancy with COVID-19, SARS, and MERS were extracted and compared by gestational age. [Table 1](#T1){ref-type="table"} shows maternal clinical characteristics, and [Table 2](#T2){ref-type="table"} shows treatment and perinatal outcomes of the three coronavirus infections in pregnancy.

###### 

Maternal clinical and laboratory characteristics of COVID-19, SARS, and MERS in pregnancy.

  **References**              **Patient no. (disease + number)**   **Trimester**   **Nationality**        **Age (years)**   **GA on Admission (weeks)**   **Fever**   **Cough**   **Myalgia**   **Malaise**   **Dyspnea**   **Signs of viral pneumonia on CT**   **Lymphopenia**
  --------------------------- ------------------------------------ --------------- ---------------------- ----------------- ----------------------------- ----------- ----------- ------------- ------------- ------------- ------------------------------------ -----------------
  Zhao et al. ([@B54])        COVID-19-1                           2nd             China                  38                25 + 5                        Yes         Yes         No            Yes           Yes           Yes                                  Yes
  Chen H. et al. ([@B9])      COVID-19-2                           3rd             China                  33                37 + 2                        No          Yes         No            No            No            Yes                                  No
  Chen H. et al. ([@B9])      COVID-19-3                           3rd             China                  27                38 + 2                        Yes         Yes         Yes           No            No            Yes                                  Yes
  Chen H. et al. ([@B9])      COVID-19-4                           3rd             China                  40                36                            No          Yes         No            No            No            Yes                                  Yes
  Chen H. et al. ([@B9])      COVID-19-5                           3rd             China                  26                36 + 2                        Yes         No          No            No            Yes           Yes                                  No
  Chen H. et al. ([@B9])      COVID-19-6                           3rd             China                  26                38 + 1                        Yes         No          Yes           Yes           No            Yes                                  Yes
  Chen H. et al. ([@B9])      COVID-19-7                           3rd             China                  26                36 + 3                        Yes         Yes         Yes           Yes           No            Yes                                  Yes
  Chen H. et al. ([@B9])      COVID-19-8                           3rd             China                  29                36 + 2                        Yes         No          No            No            No            No                                   Yes
  Chen H. et al. ([@B9])      COVID-19-9                           3rd             China                  28                38                            Yes         No          No            No            No            Yes                                  No
  Chen H. et al. ([@B9])      COVID-19-10                          3rd             China                  34                39 + 4                        Yes         No          No            No            No            Yes                                  No
  Yu et al. ([@B51])          COVID-19-11                          3rd             China                  34                39 + 6                        Yes         No          No            No            No            Yes                                  Yes
  Yu et al. ([@B51])          COVID-19-12                          3rd             China                  30                38 + 5                        Yes         No          No            No            Yes           Yes                                  No
  Yu et al. ([@B51])          COVID-19-13                          3rd             China                  31                41 + 2                        Yes         No          No            No            No            Yes                                  Yes
  Yu et al. ([@B51])          COVID-19-14                          3rd             China                  33                37                            No          Yes         No            No            No            Yes                                  Yes
  Yu et al. ([@B51])          COVID-19-15                          3rd             China                  29                40 + 4                        Yes         No          No            No            No            Yes                                  No
  Yu et al. ([@B51])          COVID-19-16                          3rd             China                  34                38 + 2                        Yes         No          No            No            No            Yes                                  Yes
  Yu et al. ([@B51])          COVID-19-17                          3rd             China                  34                38 + 4                        Yes         No          No            No            No            Yes                                  Yes
  Zhu et al. ([@B57])         COVID-19-18                          3rd             China                  25                ---                           Yes         No          No            No            No            Yes                                  ---
  Zhu et al. ([@B57])         COVID-19-19                          3rd             China                  35                ---                           Yes         No          No            No            No            Yes                                  ---
  Zhu et al. ([@B57])         COVID-19-20                          3rd             China                  35                ---                           No          Yes         No            No            No            Yes                                  ---
  Zhu et al. ([@B57])         COVID-19-21                          3rd             China                  30                ---                           Yes         No          No            No            No            Yes                                  ---
  Zhu et al. ([@B57])         COVID-19-22                          3rd             China                  30                ---                           Yes         No          No            No            No            Yes                                  ---
  Zhu et al. ([@B57])         COVID-19-23                          3rd             China                  30                ---                           Yes         Yes         No            No            No            Yes                                  ---
  Zhu et al. ([@B57])         COVID-19-24                          3rd             China                  30                ---                           Yes         Yes         No            No            No            Yes                                  ---
  Zhu et al. ([@B57])         COVID-19-25                          3rd             China                  29                ---                           Yes         Yes         No            No            No            Yes                                  ---
  Zhu et al. ([@B57])         COVID-19-26                          3rd             China                  34                ---                           Yes         No          No            No            No            Yes                                  ---
  Chen S. et al. ([@B10])     COVID-19-27                          3rd             China                  23                37 + 3                        Yes         No          No            No            Yes           Yes                                  No
  Chen S. et al. ([@B10])     COVID-19-28                          3rd             China                  34                38 + 6                        Yes         No          No            No            No            Yes                                  No
  Chen S. et al. ([@B10])     COVID-19-29                          3rd             China                  32                35                            Yes         No          No            No            No            Yes                                  No
  Wong et al. ([@B49])        SARS-1                               1st             China                  33                4                             Yes         Yes         Yes           Yes           No            Yes                                  No
  Wong et al. ([@B49])        SARS-2                               1st             China                  34                4                             Yes         No          Yes           Yes           No            Yes                                  No
  Wong et al. ([@B49])        SARS-3                               1st             China                  44                4                             Yes         Yes         Yes           Yes           Yes           Yes                                  Yes
  Wong et al. ([@B49])        SARS-4                               1st             China                  24                3                             Yes         Yes         Yes           No            No            Yes                                  No
  Wong et al. ([@B49])        SARS-5                               1st             China                  24                6                             Yes         No          Yes           Yes           No            Yes                                  Yes
  Wong et al. ([@B49])        SARS-6                               1st             China                  25                12                            Yes         Yes         Yes           Yes           Yes           Yes                                  Yes
  Wong et al. ([@B49])        SARS-7                               1st             China                  26                3                             Yes         Yes         Yes           Yes           No            Yes                                  Yes
  Wong et al. ([@B49])        SARS-8                               2nd             China                  32                26                            Yes         No          Yes           Yes           No            Yes                                  No
  Zhang et al. ([@B53])       SARS-9                               2nd             China                  34                27                            Yes         Yes         Yes           Yes           Yes           Yes                                  Yes
  Zhang et al. ([@B53])       SARS-10                              2nd             China                  ---               25 + 2                        Yes         Yes         No            Yes           No            Yes                                  Yes
  Robertson et al. ([@B36])   SARS-11                              2nd             ---                    ---               15 + 2                        Yes         Yes         No            No            No            Yes                                  Yes
  Yudin et al. ([@B52])       SARS-12                              2nd             Canada                 36                19                            Yes         Yes         No            No            Yes           Yes                                  Yes
  Wong et al. ([@B49])        SARS-13                              3rd             China                  33                31                            Yes         Yes         No            No            No            Yes                                  Yes
  Wong et al. ([@B49])        SARS-14                              3rd             China                  27                28                            Yes         Yes         Yes           Yes           Yes           Yes                                  Yes
  Wong et al. ([@B49])        SARS-15                              3rd             China                  30                30                            Yes         Yes         Yes           Yes           No            Yes                                  Yes
  Wong et al. ([@B49])        SARS-16                              3rd             China                  34                32                            Yes         Yes         Yes           Yes           No            Yes                                  Yes
  Zhang et al. ([@B53])       SARS-17                              3rd             China                  ---               30 + 2                        Yes         Yes         Yes           Yes           Yes           Yes                                  Yes
  Zhang et al. ([@B53])       SARS-18                              3rd             China                  ---               36                            Yes         Yes         No            No            No            Yes                                  Yes
  Zhang et al. ([@B53])       SARS-19                              3rd             China                  ---               40 + 4                        Yes         No          No            No            No            Yes                                  Yes
  Alfaraj et al. ([@B2])      MERS-1                               1st             Saudi Arabia           29                6                             No          No          No            No            No            ---                                  ---
  Payne et al. ([@B34])       MERS-2                               2nd             Jordanian              39                5 months                      Yes         Yes         No            Yes           No            ---                                  ---
  Assiri et al. ([@B4])       MERS-3                               2nd             Saudi Arabia           27                22                            Yes         Yes         No            No            Yes           Yes                                  ---
  Assiri et al. ([@B4])       MERS-4                               2nd             Saudi Arabia           30                23                            Yes         Yes         No            No            Yes           ---                                  ---
  Alfaraj et al. ([@B2])      MERS-5                               2nd             Saudi Arabia           39                24                            No          No          No            No            No            ---                                  ---
  Assiri et al. ([@B4])       MERS-6                               2nd             Saudi Arabia           31                24                            No          Yes         Yes           No            Yes           Yes                                  ---
  Alserehi et al. ([@B3])     MERS-7                               3rd             Saudi Arabia           33                31                            Yes         Yes         No            No            Yes           Yes                                  ---
  Malik et al. ([@B27])       MERS-8                               3rd             United Arab Emirates   32                32                            Yes         Yes         No            No            Yes           Yes                                  ---
  Assiri et al. ([@B4])       MERS-9                               3rd             Saudi Arabia           34                34                            No          No          No            No            Yes           Yes                                  ---
  Park et al. ([@B33])        MERS-10                              3rd             South Korean           39                35 + 4                        No          No          Yes           No            No            Yes                                  ---
  Assiri et al. ([@B4])       MERS-11                              3rd             Saudi Arabia           32                38                            Yes         Yes         No            No            Yes           Yes                                  ---

*GA, gestational age; COVID-19, 2019 novel coronavirus disease; SARS, severe acute respiratory syndrome coronavirus; MERS, Middle East Respiratory Syndrome coronavirus; CT, computed tomography; ---, no data*.

###### 

Treatment and perinatal outcomes of COVID-19, SARS, and MERS in pregnancy.

  **Patient no**.   **GA of delivery**   **Antiviral therapy**   **Antibiotic therapy**   **Use of corticosteroid**   **Delivery mode**   **Complication during pregnancy**           **Indication of C-section**                 **Maternal outcome**   **Neonatal outcome**
  ----------------- -------------------- ----------------------- ------------------------ --------------------------- ------------------- ------------------------------------------- ------------------------------------------- ---------------------- ----------------------
  COVID-19-1                             Yes                     No                       Yes                         ---                 ---                                         ---                                         Survived               Ongoing pregnancy
  COVID-19-2        37 + 3               Yes                     Yes                      No                          Cesarean section    Severely elevated liver enzymes             COVID-19                                    Survived               Survived
  COVID-19-3        39 + 1               Yes                     Yes                      No                          Cesarean section    ---                                         COVID-19                                    Survived               Survived
  COVID-19-4        36 + 4               Yes                     Yes                      No                          Cesarean section    ---                                         History of C-section (×2); COVID-19         Survived               Survived
  COVID-19-5        36 + 5               No                      Yes                      No                          Cesarean section    Pre-eclampsia                               Pre-eclampsia; COVID-19                     Survived               Survived
  COVID-19-6        38 + 2               No                      Yes                      No                          Cesarean section    Fetal distress                              Fetal distress; COVID-19                    Survived               Survived
  COVID-19-7        37                   No                      Yes                      No                          Cesarean section    ---                                         History of stillbirth (×2); COVID-19        Survived               Survived
  COVID-19-8        36 + 4               Yes                     Yes                      No                          Cesarean section    PROM                                        COVID-19                                    Survived               Survived
  COVID-19-9        38 + 2               Yes                     Yes                      No                          Cesarean section    Fetal distress                              Fetal distress; COVID-19                    Survived               Survived
  COVID-19-10       40 + 3               Yes                     Yes                      No                          Cesarean section    PROM                                        PROM; COVID-19                              Survived               Survived
  COVID-19-11       40                   Yes                     Yes                      Yes                         Cesarean section    ---                                         Mature; COVID-19                            Survived               Survived
  COVID-19-12       38 + 5               Yes                     Yes                      Yes                         Cesarean section    Elevated liver enzymes                      Mature; Precious fetus; Placentas racquet   Survived               Survived
  COVID-19-13       41 + 5               Yes                     Yes                      Yes                         Cesarean section    Fetal distress                              Mature; Fetal distress; COVID-19            Survived               Survived
  COVID-19-14       37                   Yes                     Yes                      Yes                         Cesarean section    ---                                         Mature; History of C-section                Survived               Survived
  COVID-19-15       40 + 6               Yes                     Yes                      No                          Cesarean section    ---                                         Mature; Failure trial vaginal               Survived               Survived
  COVID-19-16       38 + 2               Yes                     Yes                      Yes                         Cesarean section    ---                                         Mature; Parturient History of C-section;    Survived               Survived
  COVID-19-17       38 + 4               Yes                     Yes                      No                          Cesarean section    Elevated liver enzymes                      Mature; History of C-section; COVID-19      Survived               Survived
  COVID-19-18       38 + 4               ---                     ---                      ---                         Cesarean section    Fetal distress; Oligohydramnios             ---                                         Survived               Survived
  COVID-19-19       33 + 6               ---                     ---                      ---                         Cesarean section    PROM                                        ---                                         Survived               Survived
  COVID-19-20       34 + 2               ---                     ---                      ---                         Vaginal delivery    PROM; fetal distress                        ---                                         Survived               Survived
  COVID-19-21       34 + 5               ---                     ---                      ---                         Cesarean section    ---                                         ---                                         Survived               died
  COVID-19-22       39                   ---                     ---                      ---                         Cesarean section    Cholecystitis; fetal distress               ---                                         Survived               Survived
  COVID-19-23       37                   ---                     ---                      ---                         Cesarean section    Fetal distress; polyhydramnios              ---                                         Survived               Survived
  COVID-19-24       34 + 6               ---                     ---                      ---                         Cesarean section    Fetal distress                              ---                                         Survived               Survived
  COVID-19-25       31 (Twin)            ---                     ---                      ---                         Vaginal delivery    Fetal distress                              ---                                         Survived               Survived
  COVID-19-26       39                   ---                     ---                      ---                         Cesarean section    ---                                         ---                                         Survived               Survived
  COVID-19-27       37 + 4               ---                     ---                      ---                         Cesarean section    Complete placenta previa                    ---                                         Survived               Survived
  COVID-19-28       39                   ---                     ---                      ---                         Cesarean section    Acute cholecystitis, placental abruption    ---                                         Survived               Survived
  COVID-19-29       35                   ---                     ---                      ---                         Cesarean section    Complete placenta previa                    ---                                         Survived               Survived
  SARS-1            2                    Yes                     Yes                      Yes                         ---                 ---                                         ---                                         Survived               spontaneous abortion
  SARS-2            3                    Yes                     Yes                      Yes                         ---                 ---                                         ---                                         Survived               Spontaneous abortion
  SARS-3            5                    Yes                     Yes                      Yes                         ---                 ---                                         ---                                         Died                   Spontaneous abortion
  SARS-4            3                    Yes                     Yes                      Yes                         ---                 ---                                         ---                                         Survived               Spontaneous abortion
  SARS-5            1                    Yes                     Yes                      Yes                         ---                 ---                                         ---                                         Survived               Artificial abortion
  SARS-6            1                    Yes                     Yes                      Yes                         ---                 ---                                         ---                                         Survived               Artificial abortion
  SARS-7            3                    No                      Yes                      No                          ---                 ---                                         ---                                         Survived               Ongoing pregnancy
  SARS-8            26                   Yes                     Yes                      Yes                         Cesarean section    Severe condition                            Severe condition                            Survived               Survived
  SARS-9            28                   Yes                     Yes                      Yes                         Cesarean section    Severe condition                            Severe condition                            Died                   Survived
  SARS-10           38 + 4               No                      No                       No                          Cesarean section    Meconium-stained amniotic fluid             Social factor                               Survived               Survived
  SARS-11           33 + 6               No                      No                       No                          Cesarean section    Fetal distress; elevated liver enzymes      Fetal distress                              Survived               Survived
  SARS-12           38                   Yes                     Yes                      No                          Cesarean section    Complete placenta previa                    Complete placenta previa                    Survived               Survived
  SARS-13           38                   No                      Yes                      Yes                         Vaginal delivery    ---                                         ---                                         Survived               Survived
  SARS-14           33                   Yes                     Yes                      Yes                         Vaginal delivery    DIC; IUGR; oligohydramnios; preterm labor   ---                                         Survived               Survived
  SARS-15           37                   Yes                     Yes                      Yes                         Cesarean section    Renal failure; IUGR; oligohydramnios        Intrapartum nonreassuring CTG               Survived               Survived
  SARS-16           32                   Yes                     Yes                      Yes                         Cesarean section    Severe condition                            Severe condition                            Died                   Survived
  SARS-17           31 + 5               No                      No                       No                          Cesarean section    Elevated liver enzymes; fetal distress      Fetal distress                              Survived               Survived
  SARS-18           38 + 2               No                      No                       No                          Cesarean section    Fetal distress; elevated liver enzymes      Fetal distress                              Survived               Survived
  SARS-19           40 + 5               No                      No                       No                          Cesarean section    Fetal distress; elevated liver enzymes      Fetal distress                              Survived               Survived
  MERS-1            Term                 ---                     ---                      ---                         ---                 ---                                         ---                                         Survived               Ongoing pregnancy
  MERS-2            Stillbirth           ---                     ---                      ---                         ---                 ---                                         ---                                         Survived               Died
  MERS-3            Term                 ---                     ---                      ---                         ---                 ---                                         ---                                         Survived               Survived
  MERS-4            Term                 ---                     ---                      ---                         ---                 ---                                         ---                                         Survived               Survived
  MERS-5            Term                 ---                     ---                      ---                         ---                 ---                                         ---                                         Survived               Survived
  MERS-6            24                   ---                     ---                      ---                         ---                 ---                                         ---                                         Died                   Died
  MERS-7            32                   Yes                     Yes                      Yes                         ---                 ---                                         ---                                         Survived               Survived
  MERS-8            32                   Yes                     Yes                      No                          ---                 ---                                         ---                                         Died                   Survived
  MERS-9            Stillbirth           ---                     ---                      ---                         ---                 ---                                         ---                                         Survived               Died
  MERS-10           37 + 4               No                      No                       No                          ---                 ---                                         ---                                         Survived               Survived
  MERS-11           Term                 ---                     ---                      ---                         ---                 ---                                         ---                                         Died                   Survived

*GA, gestational age; COVID-19, 2019 novel coronavirus disease; SARS, severe acute respiratory syndrome coronavirus; MERS, Middle East Respiratory Syndrome coronavirus; CT, computed tomography; CTG, cardiotocography; PROM, premature rupture of membranes; DIC, disseminated intravascular coagulation; IUGR, intrauterine growth retardation; ---, no data*.

Twenty-nine cases of COVID-19 during pregnancy were found in five reports (Chen H. et al., [@B9]; Chen S. et al., [@B10]; Yu et al., [@B51]; Zhao et al., [@B54]; Zhu et al., [@B57]). One patient was infected in the second trimester (Zhao et al., [@B54]), and the others in the third trimester (Chen H. et al., [@B9]; Chen S. et al., [@B10]; Yu et al., [@B51]; Zhu et al., [@B57]). The pregnant woman infected in the second trimester had symptoms of fever, cough, malaise, and subsequently dyspnea. Blood counts showed lymphopenia, and computed tomography (CT) revealed diffused bilateral infiltrates in the lungs. She was given lopinavir/ritonavir, interferon α-2b, methylprednisolone, abidol, and gamma globulin successively. After 18 days of treatment, her condition improved, and virus nucleic acid testing for SARS-CoV-2 was negative twice. Thus, she continued with the pregnancy. On the other hand, the main symptoms of the other 28 patients infected in the third trimester were fever (89.3%), cough (35.7%), and myalgia (14.3%). CT images of 27 patients showed multiple patchy ground-glass shadows in the lungs. Three patients had elevated liver enzymes and nine developed fetal distress. In 17 patients who had detailed treatment data, all patients received oxygen support via a nasal cannula, 14 patients underwent antiviral therapy, and 16 patients underwent antibiotic treatment. As a result, 26 patients delivered via cesarean section and two patients via vaginal delivery. All neonates survived except for one. It should be noted that in the study by Zhu et al. some neonates born to mothers with COVID-19 had adverse neonatal outcomes such as premature labor, respiratory distress, thrombocytopenia accompanied by abnormal liver function, and even death (Zhu et al., [@B57]).

With regard to SARS, 19 cases have been reported during pregnancy (Zhang et al., [@B53]; Robertson et al., [@B36]; Wong et al., [@B49]; Yudin et al., [@B52]). Seven patients became infected in the first trimester, five patients in the second trimester, and seven patients in the third trimester. The most common symptoms of infected pregnant women included fever (100%), cough (78.9%), and myalgia (68.4%). Lymphocytopenia was observed in 15 pregnant women, and chest radiographs of all pregnant women indicated viral infection in the lungs. Twelve pregnant women were given antiviral drugs, 14 pregnant women were given antibiotic drugs, and 12 pregnant women were given corticosteroids. Spontaneous miscarriage was observed in four out of seven patients who were infected in the first trimester. Three of the 19 pregnant women died; however, all the neonates who were delivered in the second or third trimester survived. Two cases suffered from fetal growth restriction and oligohydramnios, four cases developed fetal distress, and there was one case of spontaneous preterm birth.

Eleven cases of pregnancy with MERS were reported (Payne et al., [@B34]; Alserehi et al., [@B3]; Assiri et al., [@B4]; Malik et al., [@B27]; Park et al., [@B33]; Alfaraj et al., [@B2]). One patient was infected in the first trimester, five patients in the second trimester, and six patients in the third trimester. Most pregnant women presented with dyspnea (72.7%), cough (63.6%), and fever (54.5%); their chest radiographs revealed typical signs of viral infection. Unfortunately, there were no detailed treatment-related data. The woman infected in the first trimester continued pregnancy after her virus nucleic acid testing for MERS-Cov turned negative. Two patients had stillbirths, and one patient developed placental abruption. Three pregnant women and three neonates died.

Diagnosis and Treatment of COVID-19 in Pregnancy {#s3}
================================================

The diagnosis of COVID-19 in pregnancy is mainly based on epidemiological history, clinical manifestations, chest radiography, and etiological tests (National Health Commission of the People\'s Republic of China, [@B31]). This is similar to the evidence of diagnosis for SARS and MERS in pregnancy. According to our literature review, most pregnant women infected by the three coronaviruses had an epidemiological contact history. Fever, cough, myalgia, and dyspnea are the major symptoms. CT images revealed typical signs of viral infection in the lungs. Nasopharynx swab or sputum was positive in the virus nucleic acid test. Lymphopenia and elevated liver enzymes were commonly seen in pregnant women with COVID-19 and SARS.

According to the seventh guidelines published by the National Health Commission of China, the treatment of COVID-19 mainly involves oxygen therapy, antiviral therapy, and supportive treatment (National Health Commission of the People\'s Republic of China, [@B31]). At present, there is no antiviral drug for the treatment of COVID-19; therefore, identifying an antiviral drug against COVID-19 in pregnancy is imperative.

Interferon-alpha is a broad-spectrum antiviral drug that activates antiviral protein genes and modulates immune cell function (Totura and Bavari, [@B42]). For SARS-CoV-1 and MERS-CoV, interferon-alpha was effective at reducing viral replication *in vitro* and *in vivo* (Cinatl et al., [@B12]; Falzarano et al., [@B15],[@B16]). Regarding its safe use in pregnant women, one systematic review suggested that interferon-alpha does not significantly increase the risk of adverse perinatal outcomes above general population rates (Yazdani Brojeni et al., [@B50]).

Lopinavir/ritonavir is a human immunodeficiency virus (HIV) protease inhibitor that was found to target the SARS-CoV-1 nonstructural protein 3CLpro *in vitro* (Lu, [@B25]). During the SARS-CoV-1 epidemic, lopinavir/ritonavir combined with ribavirin reduced the viral load and decreased the rate of death or ARDS (Chu et al., [@B11]). Lopinavir/ritonavir also increased the viral clearance rate and survival rate in patients with MERS (Chan et al., [@B8]). Lopinavir/ritonavir was also administered to pregnant women with HIV. It was found that HIV proliferation was effectively suppressed during pregnancy and through 1 year postpartum (Cohan et al., [@B13]). Furthermore, the rate of preterm deliveries, low-birth-weight neonates, stillbirths, and birth defects did not increase (Roberts et al., [@B35]; Cohan et al., [@B13]).

In addition, ribavirin and favipiravir are representative of a guanosine analog. Mechanically, ribavirin and favipiravir can inhibit virus RNA synthesis by viral RNA-dependent RNA polymerase and inhibit mRNA capping (Totura and Bavari, [@B42]). In the previous literature, ribavirin was administered to pregnant women with SARS. However, it was found that ribavirin at the concentration of typical human regimens could not significantly inhibit coronavirus replication *in vitro* (Shen et al., [@B39]). Furthermore, meta-analyses have found that its role was limited in the treatment of coronavirus-related respiratory syndromes (Stockman et al., [@B40]; Morra et al., [@B30]). The resistance might be explained by nsp14 exoribonuclease being expressed by coronavirus. As nsp14 exoribonuclease can function as an excision nucleoside analog due to its proofreading activity (Minskaia et al., [@B29]), it is speculated that COVID-19 might also be resistant to ribavirin or favipiravir (Chan et al., [@B7]).

In contrast, remdesivir, a nucleoside analog, could act against both SARS-CoV-1 and MERS-CoV *in vitro* (Sheahan et al., [@B37]). *In vivo*, remdesivir was more effective than lopinavir/ritonavir combined with interferon-β in decreasing the viral load of mice infected with MERS-CoV (Sheahan et al., [@B38]). The mechanism involved is that it can interfere with the nsp12 polymerase even in the setting of nsp14 exoribonuclease proofreading activity (Agostini et al., [@B1]). As expected, remdesivir was proved to be effective in the inhibition of SARS-CoV-2 replication *in vitro* (Wang et al., [@B45]). However, data about its safety during pregnancy are absent.

Initially, chloroquine was used as an antimalarial drug. It was later found to act against SARS-CoV-1 in primate cells either before or after exposure to the virus (Vincent et al., [@B44]). Recently, chloroquine was found to inhibit the proliferation of SARS-CoV-2 *in vitro* (Wang et al., [@B45]). The mechanism involved might be that it interferes with terminal glycosylation of ACE2 (Vincent et al., [@B44]). As to its safety in pregnancy, chloroquine was not shown to be associated with birth weight, gestational age, growth, or development of newborns, neurological development, and visual acuity in infants in the previous literature (Villegas et al., [@B43]; Ward et al., [@B47]; Divala et al., [@B14]).

Arbidol, which is a broad-spectrum antiviral drug whose mechanism involves inhibition of enveloped virus membrane fusion, has also been used (Blaising et al., [@B5]). Arbidol and arbidol mesylate were effective in suppressing the proliferation of SARS-CoV-1 *in vitro* (Khamitov et al., [@B22]). Furthermore, arbidol was effective against SARS-CoV-2 *in vitro* (Wang et al., [@B46]). In Russia, arbidol was administered to pregnant women with influenza (Bulgakova et al., [@B6]). In our the studies included in our literature review, arbidol was found to have been administered to pregnant women with COVID-19 (Yu et al., [@B51]; Zhao et al., [@B54]). However, its safety in pregnancy requires further research.

In summary, interferon-alpha, lopinavir/ritonavir, and chloroquine could be administered to pregnant women with COVID-19 after patients were fully informed of these drugs\' benefits and risks. Remdesivir and arbidol are promising antiviral drugs against COVID-19; however, their safety in pregnancy requires further research. In addition, antibiotics and corticosteroids are recommended in pregnancy with COVID-19 if necessary (Mer and Richards, [@B28]; Wong et al., [@B48]). However, antibiotics should not be used without indication, and high doses of glucocorticoids should be avoided as much as possible (National Health Commission of the People\'s Republic of China, [@B31]).

Perinatal Outcomes of COVID-19 in Pregnancy {#s4}
===========================================

Due to impaired cellular immunity and physiological changes, mild pneumonia is more likely to develop into severe pneumonia in pregnant women, and severe pneumonia is deleterious for the fetus (Lam et al., [@B23]; Goodnight and Soper, [@B17]). Thus, timely pregnancy termination may be beneficial for both mothers and infants if the disease advances. As to the mode of pregnancy termination, cesarean section is recommended (National Health Commission of the People\'s Republic of China, [@B31]). However, if the pregnant woman\'s condition does not worsen, there is a chance of having a healthy baby if pregnancy is continued. In the previous literature, pregnant women with SARS or MERS who continued pregnancy after their etiological test turned negative had favorable maternal and neonatal outcomes. However, some of them had suffered intrauterine growth restriction (IUGR), meconium-stained amniotic fluid, or fetal distress.

Pathological examination of placentas from women with COVID-19 showed various degrees of fibrin deposition inside and around the villi with local syncytial nodules, concomitant with the morphology of chorionic hemangioma or massive placental infarction (Chen S. et al., [@B10]). Further, the results from SARS-related pregnancies revealed increased intervillous, subchorionic fibrin, or extensive fetal thrombotic vasculopathy (Ng et al., [@B32]). It was speculated that these placental pathological morphological changes were caused by hypoxia during coronavirus infection, and they may result in IUGR, meconium-stained amniotic fluid, or fetal distress. Similarly, miscarriage and stillbirth could also result from hypoxia caused by coronavirus infection. Therefore, pregnant women with COVID-19 should be closely monitored, even after their nucleic acid test for SARS-Cov-2 turns negative.

In the studies included in our literature review, all pregnant women with COVID-19 and their neonates survived except for one neonate (Zhu et al., [@B57]). However, several pregnant women with SARS or MERS died or had a stillbirth, and some neonates failed to survive. It is speculated that COVID-19 during pregnancy might be less severe than SARS or MERS during pregnancy. This is consistent with the conclusion that the mortality rate of COVID-19 is less than that of SARS or MERS (Han et al., [@B19]; Liao et al., [@B24]).

Amniotic fluid, cord blood, placenta, and the fetal membrane from pregnant women with COVID-19, SARS, and MERS were all negative when tested with a viral nucleic acid test for SARS-CoV-2, SARS-CoV-1, and MERS-CoV, respectively, in the studies included in our literature review. This could be partly explained by the different distribution of their cellular receptors. The ACE2 protein is mainly expressed on lung alveolar epithelial cells and enterocytes of the small intestine (Hamming et al., [@B18]). However, ACE2 mRNA expression was found to be low in cells from the early maternal-fetal interface with single-cell RNA-sequencing technology. Hence, it is speculated that the ratio of SARS-CoV-2-infected mother-to-fetus transmission will be relatively low (Zheng et al., [@B55]). Even if SARS-CoV-2 could not transmit from mothers to babies, it could be transmitted by close contact because coronavirus also exists in the sweat glands and the distal convoluted tubules of the kidney in addition to the intestinal and respiratory tracts (To and Lo, [@B41]; Zhou et al., [@B56]). Therefore, the neonates of pregnant women with COVID-19 should be isolated for at least 14 days and should not be breastfed (National Health Commission of the People\'s Republic of China, [@B31]).

Conclusion {#s5}
==========

This research has provided some strategies for the obstetric management of pregnant women with COVID-19. To some extent, clinical characteristics were similar among pregnancies with COVID-19, SARS, and MERS. It seems that COVID-19 during pregnancy is milder than SARS and MERS during pregnancy. However, pregnant women with COVID-19 should be closely monitored, even after their etiological tests turn negative. Maternal separation is necessary even if there was no vertical transmission. Interferon-alpha, lopinavir-ritonavir, and chloroquine could be good candidates for the treatment of COVID-19 during pregnancy, but more work is needed to explore their effectiveness and safety. In addition, remdesivir and arbidol, which are potential drug treatments for COVID-19, require further research on their safety during pregnancy.
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GA

:   gestational age

COVID-19

:   2019 novel coronavirus disease

SARS

:   severe acute respiratory syndrome coronavirus

MERS

:   Middle East Respiratory Syndrome coronavirus

CoV

:   coronavirus

ACE2

:   angiotensin-converting enzyme 2

HIV

:   human immunodeficiency virus

CT

:   computed tomography

CTG

:   cardiotocography

PROM

:   premature rupture of membranes

DIC

:   disseminated intravascular coagulation

IUGR

:   intrauterine growth retardation

HIV

:   human immunodeficiency virus

N/A

:   not available.
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